Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Actinomycin D versus methotrexate for ovarian reserve in low-risk gestational trophoblastic tumor
IRCT20240514061800N5Phase 2Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of actinomycin D and methotrexate in trophoblastic tumour (2 arms), sponsored by Iran University of Medical Sciences. Primary endpoint: Anti-Mullerian hormone. Started Oct 2024; status: completed.
02
Drugs
actinomycin Dmethotrexate
03
Conditions
trophoblastic tumour
Beyond the preview
Go deeper on IRCT20240514061800N5.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240514061800N5.